Bioactivity of genistein: A review of in vitro and in vivo studies

Biomedicine and Pharmacotherapy

Volumn 76, Issue , 2015, Pages 30-38

  Ganai, Ajaz Ahmad ^a   Farooqi, Humaira ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Adipocyte; Antioxidant; Apolipoprotein; Cardioprotection; Cell mediated immunity; Colon cancer

Indexed keywords

APOLIPOPROTEIN B; CD4 ANTIGEN; CD8 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENISTEIN; NITRIC OXIDE; ANTIOXIDANT; PHYTOESTROGEN;

ADAPTIVE IMMUNITY; ADIPOCYTE; ALLERGIC DISEASE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASTHMA; BIOLOGICAL ACTIVITY; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CLOVER; COLON CANCER; DELAYED HYPERSENSITIVITY; DIET SUPPLEMENTATION; DNA DAMAGE; DRUG STRUCTURE; EPISTAXIS; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SOY FOOD; THYMOCYTE; ANIMAL; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; GENISTEIN; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; PHYTOESTROGENS;

EID: 84949212611     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.10.026     Document Type: Review

References (117)

1. Brzezinski A., Debi A. Phytoestrogens: the natural selective estrogen receptor modulators?. Eur. J. Obstet. Gynecol. Reprod. Biol. 1999, 85:47-51.
2. Ososki A.L., Kennelly E.J. Phytoestrogens: a review of the present state of research. Phytother. Res. 2003, 17:845-869.
3. Rafi M.M., Rosen R.T., Vassil A., Ho C.T., Zhang H., Ghai G., Lambert G., DiPaola R.S. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000, 20:2653-2658.
4. Kitaoka M., Kadokawa H., Sugano M., Ichikawa K., Taki M., Takaishi S., Iijima Y., Tsutsumi S., Boriboon M., Akiyama T. Prenylflavonoids: a new class of non-steroidal phytoestrogen (part 1). Isolation of 8-isopentenylnaringenin and an initial study on its structure-activity relationship. Planta Med. 1998, 64:511-515.
5. Fukutake M., Takahashi M., Ishida K., Kawamura H., Sugimura T., Wakabayashi K. Quantification of genistein and genistin in soybeans and soybean products. Food Chem. Toxicol. 1996, 34:457-461.
6. Barnes S., Peterson T.G., Coward L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J. Cell. Biochem. Suppl. 1995, 22:181-187.
7. Asahi K., Ono I., Kusakabe H., Nakamura G., Isono K. Studies on differentiation inducing substances of animal cells. I. Differenol A, a differentiation inducing substance against mouse leukemia cells. J. Antibiot. (Tokyo) 1981, 34:919-920.
8. Ogawara H., Akiyama T., Ishida J., Watanabe S., Suzuki K. A specific inhibitor for tyrosine protein kinase from Pseudomonas. J. Antibiot. (Tokyo) 1986, 39:606-608.
9. Markovits J., Linassier C., Fosse P., Couprie J., Pierre J., Jacquemin-Sablon A., Saucier J.M., Le Pecq J.B., Larsen A.K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 1989, 49:5111-5117.
10. Cassidy A. Potential tissue selectivity of dietary phytoestrogens and estrogens. Curr. Opin. Lipidol. 1999, 10:47-52.
11. Tham D.M., Gardner C.D., Haskell W.L. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab. 1998, 83:2223-2235.
12. Ganai A.A., Khan A.A., Malik Z.A., Farooqi H. Genistein modulates the expression of NF-κB and MAPK (p-38 and ERK1/2), thereby attenuating d-galactosamine induced fulminant hepatic failure in Wistar rats. Toxicol. Appl. Pharmacol. 2015, 283:139-146.
13. Clarkson T.B., Anthony M.S., Morgan T.M. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J. Clin. Endocrinol. Metab. 2001, 86:41-47.
14. Adams M.R., Golden D.L., Williams J.K., Franke A.A., Register T.C., Kaplan J.R. Soy protein containing isoflavones reduces the size of atherosclerotic plaques without affecting coronary artery reactivity in adult male monkeys. J. Nutr. 2005, 135:2852-2856.
15. Yamakoshi J., Piskula M.K., Izumi T., Tobe K., Saito M., Kataoka S., Obata A., Kikuchi M. Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits. J. Nutr. 2000, 130:1887-1893.
16. Kanazawa T., Osanai T., Zhang X.S., Uemura T., Yin X.Z., Onodera K., Oike Y., Ohkubo K. Protective effects of soy protein on the peroxidizability of lipoproteins in cerebrovascular diseases. J. Nutr. 1995, 125:639S-646S.
17. Tikkanen M.J., Wahala K., Ojala S., Vihma V., Adlercreutz H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3106-3110.
18. Wiseman H., O'Reilly J.D., Adlercreutz H., Mallet A.I., Bowey E.A., Rowland I.R., Sanders T.A. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am. J. Clin. Nutr. 2000, 72:395-400.
19. Ryan-Borchers T.A., Park J.S., Chew B.P., McGuire M.K., Fournier L.R., Beerman K.A. Soy isoflavones modulate immune function in healthy postmenopausal women. Am. J. Clin. Nutr. 2006, 83:1118-1125.
20. Hodgson J.M., Puddey I.B., Croft K.D., Mori T.A., Rivera J., Beilin L.J. Isoflavonoids do not inhibit in vivo lipid peroxidation in subjects with high-normal blood pressure. Atherosclerosis 1999, 145:167-172.
21. Samman S., Lyons W., all P.M., Chan G.S., Smith S.J., Petocz P. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis 1999, 147:277-283.
22. Vega-Lopez S., Yeum K.J., Lecker J.L., Ausman L.M., Johnson E.J., Devaraj S., Jialal I., Lichtenstein A.H. Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am. J. Clin. Nutr. 2005, 81:43-49.
23. Ruiz-Larrea M.B., Mohan A.R., Paganga G., Miller N.J., Bolwell G.P., Rice-Evans C.A. Antioxidant activity of phytoestrogenic isoflavones. Free Radic. Res. 1997, 26:63-70.
24. Kapiotis S., Hermann M., Held I., Seelos C., Ehringer H., Gmeiner B.M. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb. Vasc. Biol. 1997, 17:2868-2874.
25. Wright J.S., Johnson E.R., DiLabio G.A. Predicting the activity of phenolic antioxidants: theoretical method, analysis of substituent effects, and application to major families of antioxidants. Am. Chem. Soc. 2001, 123:1173-1183.
26. Heim K.E., Tagliaferro A.R., Bobilya D.J. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J. Nutr. Biochem. 2002, 13:572-584.
27. Choi C., Cho H., Park J., Cho C., Song Y. Suppressive effects of genistein on oxidative stress and NFkappaB activation in RAW 264.7 macrophages. Biotechnol. Biochem. 2003, 67:1916-1922.
28. Suzuki K., Koike H., Matsui H., Ono Y., Hasumi M., Nakazato H., Okugi H., Sekine Y., Oki K., Ito K., et al. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int. J. Cancer 2002, 99:846-852.
29. Raschke M., Rowland I.R., Magee P.J., Pool-Zobel B.L. Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress. Carcinogenesis 2006, 27:2322-2330.
30. Boersma B.J., D'Alessandro T., Benton M.R., Kirk M., Wilson L.S., Prasain J., Botting N.P., Barnes S., Darley-Usmar V.M., Patel R.P. Neutrophil myeloperoxidase chlorinates and nitrates soy isoflavones and enhances their antioxidant properties. Free Radic. Biol. Med. 2003, 35:1417-1430.
31. Yellayi S., Naaz A., Szewczykowski M.A., Sato T., Woods J.A., Chang J., Segre M., Allred C.D., Helferich W.G., Cooke P.S. The phytoestrogen genistein induces thymic and immune changes: a human health concern?. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7616-7621.
32. Holmdahl R., Jansson L. Estrogen-induced suppression of collagen arthritis. III. Adult thymectomy does not affect the course of arthritis or the estrogen-mediated suppression of T-cell immunity. Brain Behav. Immun. 1988, 2:123-132.
33. Hoek A., van K., asteren Y., de H., aan-Meulman M., Hooijkaas H., Schoemaker J., Drexhage H.A. Analysis of peripheral blood lymphocyte subsets, NK cells, and delayed type hypersensitivity skin test in patients with premature ovarian failure. Am. J. Reprod. Immunol. 1995, 33:495-502.
34. Salem M.L., Matsuzaki G., Kishihara K., Madkour G.A., Nomoto K. beta-estradiol suppresses T cell-mediated delayed-type hypersensitivity through suppression of antigen-presenting cell function and Th1 induction. Int. Arch. Allergy Immunol. 2000, 121:161-169.
35. O'Connor T.P., Liesen D.A., Mann P.C., Rolando L., Banz W.J. A high isoflavone soy protein diet and intravenous genistein delay rejection of rat cardiac allografts. J. Nutr. 2002, 132:2283-2287.
36. Cohen J.H., Danel L., Cordier G., Saez S., Revillard J.P. Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J. Immunol. 1983, 131:2767-2771.
37. Gulshan S., McCruden A.B., Stimson W.H. Oestrogen receptors in macrophages. Scand. J. Immunol. 1990, 31:691-697.
38. Suenaga R., Evans M.J., Mitamura K., Rider V., Abdou N.I. Peripheral blood T cells and monocytes and B cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. J. Rheumatol. 1998, 25:1305-1312.
39. Yellayi S., Teuscher C., Woods J.A., Welsh T.H., Tung K.S., Nakai M., Rosenfeld C.S., Lubahn D.B., Cooke P.S. Normal development of thymus in male and female mice requires estrogen/estrogen receptor-alpha signaling pathway. Endocrine 2000, 12:207-213.
40. Guo T.L., Zhang X.L., Bartolucci E., McCay J.A., White K.L., You L. Genistein and methoxychlor modulate the activity of natural killer cells and the expression of phenotypic markers by thymocytes and splenocytes in F0 and F1 generations of Sprague-Dawley rats. Toxicology 2002, 172:205-215.
41. Zoppi G., Zamboni G., Bassani N., Vazzoler G. Gammaglobulin level and soy-protein intake in early infancy. Eur. J. Pediatr. 1979, 131:61-69.
42. Zoppi G., Gerosa F., Pezzini A., Bassani N., Rizzotti P., Bellini P., Todeschini G., Zamboni G., Vazzoler G., Tridente G. Immunocompetence and dietary protein intake in early infancy. J. Pediatr. Gastroenterol. Nutr. 1982, 1:175-182.
43. Park O.J., Surh Y.J. Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicol. Lett. 2004, 150:43-56.
44. Wang H.K. The therapeutic potential of flavonoids. Exp. Opin. Investig. Drugs 2000, 9:2103-2119.
45. Sarkar F.H., Li Y. Soy isoflavones and cancer prevention. Cancer Invest. 2003, 21:744-757.
46. Qi W., Weber C.R., Wasland K., Roy H., Wali R., Joshi S., Savkovic S.D. Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. Am. J. Physiol. Gastrointest Liver Physiol. 2011, 300:G264-G272.
47. Qi W., Weber C.R., Wasland K., Savkovic S.D. Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer 2011, 11:219.
48. Dijkers P.F., Medema R.H., Pals C., Banerji L., Thomas N.S., Lam E.W., Burgering B.M., Raaijmakers J.A., Lammers J.W., Koenderman L., Coffer P.J. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. 2000, 20:9138-9148.
49. Dalu A., Haskell J.F., Coward L., Lamartiniere C.A. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. Prostate 1998, 37:36-43.
50. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262:5592-5595.
51. Rajah T.T., Du N., Drews N., Cohn R. Genistein in the presence of 17beta-estradiol inhibits proliferation of ERbeta breast cancer cells. Pharmacology 2009, 84:68-73.
52. Bielecki A., Roberts J., Mehta R., Raju J. Estrogen receptor-β mediates the inhibition of DLD-1 human colon adenocarcinoma cells by soy isoflavones. Nutr. Cancer 2011, 63:139-150.
53. Kim E.J., Shin H.K., Park J.H. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. J. Med. Food 2005, 8:431-438.
54. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
55. Samuels Y., Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 2006, 18:77-82.
56. Sheng H., Shao J., Townsend C.M., Evers B.M. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 2003, 52:1472-1478.
57. Medema R.H., Kops G.J., Bos J.L., Burgering B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787.
58. Eto I. Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells. Cancer Cell Int. 2006, 6:20.
59. Shen J.C., Klein R.D., Wei Q., Guan Y., Contois J.H., Wang T.T., Chang S., Hursting S.D. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol. Carcinog. 2000, 29:92-102.
60. Jones J.T., Akita R.W., Sliwkowski M.X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 1999, 447:227-231.
61. Rand A., Glenn K.S., Alvares C.P., White M.B., Thibodeau S.M., Karnes W.E. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. Cancer Lett. 1996, 98:183-191.
62. Rodrigues N.R., Rowan A., Smith M.E., Kerr I.B., Bodmer W.F., Gannon J.V., Lane D.P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7555-7559.
63. Jaiswal A.S., Narayan S. p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. J. Biol. Chem. 2001, 276:18193-18199.
64. Gerdes H. Colon cancer and the p53 oncogene. Gastroenterology 1991, 100:842-843.
65. Pool-Zobel B.L., Adlercreutz H., Glei M., Liegibel U.M., Sittlingon J., Rowland I., Wähälä K., Rechkemmer G. Isoflavonoids and lignans have different potentials to modulate oxidative genetic damage in human colon cells. Carcinogenesis 2000, 21:1247-1252.
66. Davis J.N., Kucuk O., Djuric Z., Sarkar F.H. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic. Biol. Med. 2001, 30:1293-1302.
67. Mitchell J.H., Collins A.R. Effects of a soy milk supplement on plasma cholesterol levels and oxidative DNA damage in men-a pilot study. Eur. J. Nutr. 1999, 38:143-148.
68. St C., lair R.W. Estrogens and atherosclerosis: phytoestrogens and selective estrogen receptor modulators. Curr. Opin. Lipidol. 1998, 9:457-463.
69. Vitolins M.Z., Anthony M., Burke G.L. Soy protein isoflavones, lipids and arterial disease. Curr. Opin. Lipidol. 2001, 12:433-437.
70. Anthony M.S., Clarkson T.B., Hughes C.L., Morgan T.M., Burke G.L. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J. Nutr. 1996, 126:43-50.
71. Anthony M.S., Clarkson T.B., Bullock B.C., Wagner J.D. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2524-2531.
72. Clarkson T.B., Anthony M.S., Williams J.K., Honore E.K., Cline J.M. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. Proc. Soc. Exp. Biol. Med. 1998, 217:365-368.
73. Crouse J.R., 3rd M., organ T., Terry J.G., Ellis J., Vitolins M., Burke G.L. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch. Intern. Med. 1999, 159:2070-2076.
74. Washburn S., Burke G.L., Morgan T., Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999, 6:7-13.
75. Merz-Demlow B.E., Duncan A.M., Wangen K.E., Xu X., Carr T.P., Phipps W.R., Kurzer M.S. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am. J. Clin. Nutr. 2000, 71:1462-1469.
76. Wangen K.E., Duncan A.M., Xu X., Kurzer M.S. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am. J. Clin. Nutr. 2001, 73:225-231.
77. Yao Z., Tran K., McLeod R.S. Intracellular degradation of newly synthesized apolipoprotein B. J. Lipid Res. 1997, 38:1937-1953.
78. Davis R.A. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim. Biophys. Acta 1999, 1440:1-31.
79. Shelness G.S., Sellers J.A. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 2001, 12:151-157.
80. Wetterau J.R., Gregg R.E., Harrity T.W., Arbeeny C., Cap M., Connolly F., Chu C.H., George R.J., Gordon D.A., Jamil H., et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998, 282:751-754.
81. Jamil H., Dickson J.K.J., r, Chu C.H., Lago M.W., Rinehart J.K., Biller S.A., Gregg R.E., Wetterau J.R. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J. Biol. Chem. 1995, 270:6549-6554.
82. Borradaile N.M., de D., reu L.E., Wilcox L.J., Edwards J.Y., Huff M.W. Soya phytoestrogens, genistein and daidzein, decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms. Biochem. J. 2002, 366:531-539.
83. Lin M.C., Gordon D., Wetterau J.R. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J. Lipid Res. 1995, 36:1073-1081.
84. Haghpassand M., Wilder D., Moberly J.B. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J. Lipid Res. 1996, 37:1468-1480.
85. Wilcox L.J., Barrett P.H., Newton R.S., Huff M.W. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB. Arterioscler Thromb. Vasc. Biol. 1999, 19:939-949.
86. Lovati M.R., Manzoni C., Canavesi A., Sirtori M., Vaccarino V., Marchi M., Gaddi G., Sirtori C.R. Soybean protein diet increases low density lipoprotein receptor activity in mononuclear cells from hypercholesterolemic patients. J. Clin. Invest. 1987, 80:1498-1502.
87. Baum J.A., Teng H., Erdman J.W., Weigel R.M., Klein B.P., Persky V.W., Freels S., Surya P., Bakhit R.M., Ramos E., et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am. J. Clin. Nutr. 1998, 68:545-551.
88. Wilcox L.J., Barrett P.H., Huff M.W. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J. Lipid Res. 1999, 40:1078-1089.
89. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H., Newton R.S., Huff M.W. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology 1999, 140:5293-5302.
90. Wilcox L.J., Barrett P.H., Newton R.S., Huff M.W. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB. Arterioscler. Thromb. Vasc. Biol. 1999, 19:939-949.
91. Seekamp A., Till G.O., Mulligan M.S., Paulson J.C., Anderson D.C., Miyasaka M., Ward P.A. Role of selectins in local and remote tissue injury following ischemia and reperfusion. Am. J. Pathol. 1994, 144:592-598.
92. Harlan J.M. Consequences of leukocyte-vessel wall interactions in inflammatory and immune reactions. Semin. Thromb. Hemost. 1987, 13:434-444.
93. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1990, 62:3-6.
94. Weyrich A.S., Buerke M., Albertine K.H., Lefer A.M. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J. Leukoc. Biol. 1995, 57:45-55.
95. Smith C.W., Entman M.L., Lane C.L., Beaudet A.L., Ty T.I., Youker K., Hawkins H.K., Anderson D.C. Adherence of neutrophils to canine cardiac myocytes in vitro is dependent on intercellular adhesion molecule-1. J. Clin. Invest. 1991, 88:1216-1223.
96. Deodato B., Altavilla D., Squadrito G., Campo G.M., Arlotta M., Minutoli L., Saitta A., Cucinotta D., Calapai G., Caputi A.P., et al. Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury. Br. J. Pharmacol. 1999, 128:1683-1690.
97. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262:5592-5595.
98. Weber C., Negrescu E., Erl W., Pietsch A., Frankenberger M., Ziegler-Heitbrock H.W., Siess W., Weber P.C. Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. J. Immunol. 1995, 155:445-451.
99. Kim H.K., Nelson-Dooley C., Della-Fera M.A., Yang J.Y., Zhang W., Duan J., Hartzell D.L., Hamrick M.W., Baile C.A. Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J. Nutr. 2006, 136:409-414.
100. Wise L.S., Green H. Participation of one isozyme of cytosolic glycerophosphate dehydrogenase in the adipose conversion of 3T3 cells. J. Biol. Chem. 1979, 254:273-275.
101. Penza M., Montani C., Romani A., Vignolini P., Pampaloni B., Tanini A., Brandi M.L., Alonso-Magdalena P., Nadal A., Ottobrini L., et al. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology 2006, 147:5740-5751.
102. Gregoire F.M., Smas C.M., Sul H.S. Understanding adipocyte differentiation. Physiol. Rev. 1998, 78:783-809.
103. Naaz A., Yellayi S., Zakroczymski M.A., Bunick D., Doerge D.R., Lubahn D.B., Helferich W.G., Cooke P.S. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology 2003, 144:3315-3320.
104. Park H.J., Della-Fera M.A., Hausman D.B., Rayalam S., Ambati S., Baile C.A. Genistein inhibits differentiation of primary human adipocytes. J. Nutr. Biochem. 2009, 20:140-148.
105. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994, 8:1224-1234.
106. Si H., Liu D. Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. J. Nutr. 2008, 138:297-304.
107. Higuchi H., Granger D.N., Saito H., Kurose I. Assay of antioxidant and antiinflammatory activity of nitric oxide in vivo. Methods Enzymol. 1999, 301:424-436.
108. Iturry-Yamamoto G., Alves A.A., Picon P.D. Antiatherogenic effects of endothelium-derived relaxing factor (nitric oxide). Arq. Bras. Cardiol. 1997, 69:349-357.
109. Asakura H., Okudaira M., Ontachi Y., Mizutani T., Omote M., Yoshida T., Kaneda M., Yamazaki M., Morishita E., Takami A., et al. Antithrombotic role of nitric oxide in rats under physiological conditions. Thromb. Haemost. 2004, 91:71-75.
110. Li D.Y., Tao L., Liu H., Christopher T.A., Lopez B.L., Ma X.L. Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis 2006, 11:923-930.
111. Squadrito F., Altavilla D., Morabito N., Crisafulli A., D'Anna R., Corrado F., Ruggeri P., Campo G.M., Calapai G., Caputi A.P., Squadrito G. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 2002, 163:339-347.
112. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263.
113. Sieck G.C. Genome and hormones: an integrated approach to gender differences in physiology. J. Appl. Physiol. 2001, 91:1485-1486.
114. Chambliss K.L., Shaul P.W. Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 2002, 23:665-686.
115. Liu D., Jiang H., Grange R.W. Genistein activates the 3',5'-cyclic adenosine monophosphate signaling pathway in vascular endothelial cells and protects endothelial barrier function. Endocrinology 2005, 146:1312-1320.
116. Kim H., Peterson T.G., Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr. 1998, 68:1418S-1425S.
117. Hwang T.C., Wang F., Yang I.C., Reenstra W.W. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am. J. Physiol. 1997, 273:C988-998.